Effects of Tocilizumab in COVID-19 patients: a cohort study

Effects of Tocilizumab in COVID-19 patients: a cohort study

Abstract Background Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with progressive respiratory failure from SARS-CoV-2....

Full description

Bibliographic Details
Main Authors: Christine A. Vu, Kailynn J. DeRonde, Ana D. Vega, Meshell Maxam, Gregory Holt, Yoichiro Natori, Jose Gonzales Zamora, Veronica Salazar, Renata Boatwright, Stephen R. Morris, Daniela de Lima Corvino, Anmary Fernandez Betances, Leah Colucci, James Keegan, Andy Lopez, Andrew Hany Rezk, Yvette Rodriguez, Gabriela M. Moraru, Susanne Doblecki, David J. De La Zerda, Lilian M. Abbo
Format: Article
Language:English
Published: BMC 2020-12-01
Series:BMC Infectious Diseases
Subjects:
Coronavirus
COVID-19
Tocilizumab
Cytokine release syndrome
Online Access:https://doi.org/10.1186/s12879-020-05701-4

Internet

https://doi.org/10.1186/s12879-020-05701-4

Similar Items